Sunshine Biopharma Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
(firmenpresse) - MONTREAL -- (Marketwire) -- 08/15/12 -- Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal (Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.08.2012 - 06:30 Uhr
Sprache: Deutsch
News-ID 1142567
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MONTREAL
Phone:
Kategorie:
Investment Services & Trading
Anmerkungen:
Diese Pressemitteilung wurde bisher 138 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sunshine Biopharma Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sunshine Biopharma Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
